期(qi)刊(kan)中文名:治療輸送ISSN:2041-5990E-ISSN:2041-6008
該雜(za)志(zhi)國際簡稱:THER DELIV,是(shi)由(you)出版(ban)商Future Medicine Ltd.出版(ban)的(de)一(yi)本致力(li)于發(fa)布(bu)--研究(jiu)新成(cheng)(cheng)果(guo)的(de)的(de)專業(ye)學術(shu)期刊(kan)(kan)(kan)。主要發(fa)表刊(kan)(kan)(kan)登有創(chuang)見的(de)學術(shu)論文文章、行業(ye)最(zui)(zui)新科研成(cheng)(cheng)果(guo),扼要報道(dao)階段性研究(jiu)成(cheng)(cheng)果(guo)和重(zhong)要研究(jiu)工作的(de)最(zui)(zui)新進展,選載對(dui)學科發(fa)展起指導作用的(de)綜述與專論,促進學術(shu)發(fa)展,為(wei)廣大讀者服務。該刊(kan)(kan)(kan)是(shi)一(yi)本國際優秀雜(za)志(zhi),在國際上(shang)有很高(gao)的(de)學術(shu)影響(xiang)力(li)。
《Therapeutic Delivery》是一本以English為主的(de)(de)(de)未開放獲(huo)取(qu)(qu)國際(ji)優秀期(qi)刊,中文(wen)名稱(cheng)治療輸送(song),本刊主要(yao)出版、報道領(ling)域(yu)的(de)(de)(de)研究動態以及在該領(ling)域(yu)取(qu)(qu)得的(de)(de)(de)各方(fang)面(mian)的(de)(de)(de)經驗和科研成果(guo),介紹該領(ling)域(yu)有關本專(zhuan)業的(de)(de)(de)最(zui)新進展(zhan)(zhan),探討行業發(fa)展(zhan)(zhan)的(de)(de)(de)思路和方(fang)法,以促進學術信息交流(liu),提(ti)高行業發(fa)展(zhan)(zhan)。該刊已被(bei)國際(ji)權(quan)威(wei)數據庫SCIE收錄(lu),為該領(ling)域(yu)相關學科的(de)(de)(de)發(fa)展(zhan)(zhan)起到(dao)了(le)(le)良好(hao)的(de)(de)(de)推(tui)動作(zuo)用,也得到(dao)了(le)(le)本專(zhuan)業人(ren)員(yuan)的(de)(de)(de)廣泛認可。該刊最(zui)新影響(xiang)因(yin)子為3,最(zui)新CiteScore 指(zhi)數為5.5。
Therapeutic Delivery is an academic journal dedicated to drug delivery systems and therapeutic strategies, with the goal of advancing drug delivery science, including new drug carriers, targeting strategies, nanotechnology, biomaterials, drug release systems, and more. Through original research, reviews, comments, and case reports, this journal provides a platform for researchers, clinicians, and the pharmaceutical industry to exchange and share the latest research findings. The content of the magazine covers multiple aspects of drug delivery science, including but not limited to the design and optimization of drug carriers, such as liposomes, polymer nanoparticles, metal nanoparticles, etc; Research on the biocompatibility and biodegradability of drug delivery systems; In vitro and in vivo evaluation methods for drug delivery systems; Application of drug delivery system in disease treatment, such as cancer, cardiovascular disease, diabetes, etc; Preclinical studies and clinical trial results of drug delivery systems.
按JIF指標學(xue)科(ke)分(fen)區 |
學科:PHARMACOLOGY & PHARMACY
收錄子集:ESCI
分區:Q2
排名:136 / 354
百分位:
61.7% |
按(an)JCI指標學科分區 |
學科:PHARMACOLOGY & PHARMACY
收錄子集:ESCI
分區:Q2
排名:163 / 354
百分位:
54.1% |
JCR分區:JCR分(fen)(fen)(fen)(fen)區(qu)(qu)來自(zi)科(ke)睿(rui)唯(wei)安公司,JCR是(shi)一(yi)個獨特的(de)(de)(de)(de)多學科(ke)期(qi)(qi)刊(kan)(kan)評(ping)價工(gong)具(ju),為(wei)(wei)唯(wei)一(yi)提供(gong)基于引文數據的(de)(de)(de)(de)統計(ji)信息的(de)(de)(de)(de)期(qi)(qi)刊(kan)(kan)評(ping)價資(zi)源。每(mei)年發布的(de)(de)(de)(de)JCR分(fen)(fen)(fen)(fen)區(qu)(qu),設置了254個具(ju)體學科(ke)。JCR分(fen)(fen)(fen)(fen)區(qu)(qu)根據每(mei)個學科(ke)分(fen)(fen)(fen)(fen)類按照期(qi)(qi)刊(kan)(kan)當(dang)年的(de)(de)(de)(de)影響因子高低將期(qi)(qi)刊(kan)(kan)平(ping)均分(fen)(fen)(fen)(fen)為(wei)(wei)4個區(qu)(qu),分(fen)(fen)(fen)(fen)別為(wei)(wei)Q1、Q2、Q3和Q4,各(ge)占25%。JCR分(fen)(fen)(fen)(fen)區(qu)(qu)中期(qi)(qi)刊(kan)(kan)的(de)(de)(de)(de)數量(liang)是(shi)均勻(yun)分(fen)(fen)(fen)(fen)為(wei)(wei)四個部(bu)分(fen)(fen)(fen)(fen)的(de)(de)(de)(de)。
學科類別 | 分區 | 排名 | 百分位 |
大類:Pharmacology, Toxicology and Pharmaceutics 小類:Pharmaceutical Science | Q2 | 64 / 183 |
65% |
該雜(za)(za)志(zhi)是一本(ben)國(guo)際優秀(xiu)雜(za)(za)志(zhi),在國(guo)際上有較(jiao)高的學(xue)術(shu)影(ying)響力,行(xing)業(ye)(ye)(ye)關注(zhu)度(du)很高,已被(bei)國(guo)際權威數據庫SCIE收(shou)錄,該雜(za)(za)志(zhi)在綜合專(zhuan)業(ye)(ye)(ye)領域專(zhuan)業(ye)(ye)(ye)度(du)認可很高,對(dui)稿(gao)(gao)件內(nei)容的創新(xin)性(xing)和學(xue)術(shu)性(xing)要(yao)求很高,作為一本(ben)國(guo)際優秀(xiu)雜(za)(za)志(zhi),一般(ban)投稿(gao)(gao)過審(shen)時間(jian)都較(jiao)長,投稿(gao)(gao)過審(shen)時間(jian)平(ping)均 ,如果想(xiang)投稿(gao)(gao)該刊(kan)要(yao)做好時間(jian)安排。版面(mian)費不祥。該雜(za)(za)志(zhi)近兩年(nian)未(wei)被(bei)列入(ru)預警名(ming)單,建議您(nin)投稿(gao)(gao)。如您(nin)想(xiang)了解(jie)更多投稿(gao)(gao)政(zheng)策及投稿(gao)(gao)方(fang)案,請咨詢客服。
若(ruo)用戶(hu)需要出版服(fu)務,請聯系出版商。